White House to Reallocate Vaccines Based on State Demand
(Bloomberg) -- President Joe Biden's administration told governors Tuesday that it would begin reallocating vaccines that go unclaimed by states -- essentially clawing back unwanted doses from places where the pace of shots is lagging in order to steer them elsewhere, three people familiar with the call said.
The White House told governors about the switch during a weekly call with the state leaders. Biden is due to speak Tuesday afternoon at the White House about the Covid response.
Vaccine uptake has varied significantly by state, but the U.S. has been allocating the supply evenly based on adult populations, regardless of how many doses are being used. The plan will see weekly unclaimed doses essentially repooled for any state to claim, including those with higher demand, the people said. States that don't order their full allocation one week can still request it on any following week, two of the people said.
The seven-day average of shots has fallen to 2.3 million, from 3.4 million, in about three weeks, according to data compiled by the Bloomberg Vaccine Tracker. The U.S. administered 1.2 million shots Monday, the lowest daily total since February, though Monday is typically a slower day for vaccination data.
Karen Lynch, the chief executive officer of CVS Health Corp., said the pharmacy company was pleased with the new policy.
“The White House has kind of had a recognition that they needed to be a little bit more flexible in getting vaccines to where vaccines needed to be,” she said in a phone interview. “We'll have the flexibility to move our vaccines around to where the demand is.”
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.